Expert Statement: Rudolf Staudigl, Wacker Chemie
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
Expert Statement: Uwe Bergmann, Henkel
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
Expert Statement: Martin Babilas, Altana
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
Expert Statement: Wijnand Bruinsma, AkzoNobel
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
14.01.2021 • Topics • Technology
Think Big – Prove Small – Scale Fast
Digital twin systems transform business by accelerating holistic understanding, optimal decision-making, and effective action.
15.12.2020 • Webinar
High Purity Synthetic Carbon Adsorbents for Challenging Separations
Novel nanoporous materials for purifications and separations of gas and liquid streams.
09.12.2020 • Product
High-Performance Nanoparticle-Free Gold Ink
OrelTech, a Berlin, Germany-based producer of conductive inks, has launched OTech Aurum, a nanoparticle-free gold ink. OTech Aurum gold ink has superior conductivity to all existing gold nanoparticle-based inks. The same device performance can be achieved by using up to 60% less material at the fraction of the production price.
Safety Is a Mindset, not a Department
Alexis Pey, Global SHE & Process Safety Manager at Dutch holding Stahl, talks about the company’s safety culture involving the whole organization.
04.12.2020 • Topics • Innovation
A New Standard for Process Simulation — and Beyond
Hafnium Labs is tackling one of the toughest challenges in chemical R&D: Obtaining reliable physical property data — fast.
A Virtual Formulation Assistant
BASF has created ZoomLab, a virtual formulation prediction and optimization tool, to help address the challenges of drug product development.
Changes in Trade with the United Kingdom
On Dec. 31, 2020, the UK will leave the EU single market and customs union. Regardless of any agreement reached with the EU, the end of the Brexit transition period will affect citizens, businesses, as well as travel between the UK and EU. Therefore, businesses need to prepare themselves for the upcoming changes.
Challenges Facing Pharmaceutical Manufacturing
Sean Diver, president of DCAT speaks about the pharmaceutical industry’s role during the Covid-19 pandemic, trends in drug manufacturing, and key issues for the EU pharmaceutical industry.
The Coronavirus Crisis: Challenges and Opportunities for CMOs, CDMOs and CROs
The coronavirus crisis caused by the Covid-19 pandemic has uncovered problems that have been smoldering beneath the surface of the pharmaceutical industry — including CMOs/CDMOs and CROs — and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Andrew Henderson, Sterling Pharma Solutions
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Mark Quick, Recipharm
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Peter Halkjaer-Knudsen, Raybow Pharmaceuticals
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Matthew Moorcroft, Lonza
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Alan Walker, Kaneka
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: David Zimmermann, Kalexsyn
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Andrew Thompson, J-Star
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Jean-Luc Herbeaux, Hovione
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: GianMarco Negrisoli, Flamma
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Peter Pekos, Dalton Pharma Services
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Michael Quirmbach, CordenPharma
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
09.10.2020 • Product
Optimal Time-to-Market for Life-Saving Biopharmaceuticals
Rentschler Biopharma offers bioprocess development and cGMP manufacturing for high-quality biopharmaceuticals. The company’s strength lies in its extensive experience with complex proteins and exceptional track record of over 100 different therapeutic protein formats.
05.10.2020 • Whitepaper
Advancing Sustainable Chemical Solutions
Without products based directly or indirectly on chemicals, life as we know it would be unsustainable. According to various sources, more than 95% of the products around us are either made by the chemical industry or involve at least one chemical process step in their manufacture.
Into the Crucible: Will the European Chemicals Industry Rise to the Circularity Challenge?
Chemicals are a critical, but often overlooked, factor of success for a circular economy. 96% of all products on European markets, from food to medical treatments, from buildings to consumer electronics, rely on chemicals, so this shouldn’t come as a surprise. But what does circularity mean for the future of the chemicals industry? Should it embrace circular systems or resist them?
21.09.2020 • Topics • Technology
Digital Transformation and Smart Manufacturing
Andreas Helget, Managing Director of Yokogawa Germany, about the importance of digital transformation on the way to autonomous systems.
17.09.2020 • Topics • Innovation
Accelerated Drug Discovery
In January, Schrödinger, a provider of integrated software solutions, and the life sciences company Bayer announced a 5-year technology alliance to develop a comprehensive de novo design solution to accelerate the discovery of innovative, high-quality drugs.
The Importance of Innovation for Future Success
Innovative strength has been a cornerstone of Bachem’s business success since the founding nearly 50 years ago. Günther Loidl, Chief Technology Officer for Bachem Holding, talks about a new innovation management system that will further heighten the importance of innovation in the future.
Facing Strong Headwinds
So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.
Expansions in High-Potency API Manufacturing
DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.
Understanding the Requirements of Safe HPAPI Manufacturing
The pharmaceutical industry is increasingly focused on the development of specialized drug products with new treatment modalities, including previously undruggable targets for oncology and other areas.
Continuation Rather than a Change
China`s 14th Five-Year Plan (FYP) covering the period from 2021 to 2025 will only be published after its acceptance by the National People`s Congress in March 2021.
11.09.2020 • Topics • Innovation
Glucose Control of Bioprocesses
Online Monitoring and Control of Bioreactors by Mid-Infrared Spectroscopy
